Immuron Ltd ADR Overview
Industry: Biotechnology
Sector: Healthcare
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia. Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It o Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Immuron Ltd ADR into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
No latest earnings report cached yet
Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar
Headline from Yahoo Finance: Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar.
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
Headline from Yahoo Finance: Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year.
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
Headline from GlobeNewswire: Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year.
Earnings Per Share
Return on Equity
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.